Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Recruiting · Phase 3 · NCT06819007
Conditions: Ovarian Cancer
At a glance
- Research payments reported, 2025
- $603,497
- U.S. investigators named
- 17
- Sites paid
- 18
- Planned or actual enrollment
- 582
About the trial
- Sponsor
- Daiichi Sankyo
- Tested
- Trastuzumab Deruxtecan (drug), Bevacizumab (drug)
- Dates
- Started 2025-03-19; completion 2032-01-31
- Results posted
- Not yet
This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry \[IHC\] 3+/2+/1+) advanced high-grade epithelial ovarian cancer.
From ClinicalTrials.gov, last updated 2026-10-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $603,497 in research payments for this study in 2025 (30 payments).
Products named: Enhertu
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Jo Marie T. Janco, M.D. Gynecologic Oncology · La Jolla, CA
- Debra S. Brandt, D.O. Hematology & Oncology · Jupiter, FL
- Scott E. Jordan, M.D. OB-GYN (Obstetrics & Gynecology) · Fort Lauderdale, FL
- Brian M. Slomovitz, M.D. Gynecologic Oncology · Fort Lauderdale, FL
- Destin R. Black, MD Gynecologic Oncology · Shreveport, LA
- Rafael Gonzalez, MD OB-GYN (Obstetrics & Gynecology) · Boston, MA
- Fong Liu, M.D. Gynecologic Oncology · Towson, MD
- Megan M. Petersen, M.D. Gynecologic Oncology · Billings, MT
- Linda Van Le, MD Gynecologic Oncology · Chapel Hill, NC
- Stephanie Blank, MD Gynecologic Oncology · New York, NY
- Julia Fehniger, M.D. Gynecologic Oncology · New York, NY
- Bhavana Pothuri, M.D. Gynecologic Oncology · New York, NY
- Christopher J. Darus, MD Gynecologic Oncology · Portland, OR
- Katherine Hicks-courant, M.D. Gynecologic Oncology · Lancaster, PA
- Sarah P. Huepenbecker, M.D. Gynecologic Oncology · Easton, PA
- Amanda J. Podolski, M.D. Internal Medicine · Philadelphia, PA
- David C. Starks, MD Gynecologic Oncology · Sioux Falls, SD
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Greater Baltimore Medical Center, MD $80,000
- Trials365, Llc $48,165
- Avera Mckennan Hospital & University Health Center, SD $41,000
- Scripps Mercy Hospital, CA $40,000
- New York University School of Medicine $40,000
- University of North Carolina at Chapel Hill $40,000
- Providence St Jude Medical Center $35,000
- Providence Health System $35,000
- The Valley Hospital $35,000
- Sacred Heart Hospital $33,998
- Intermountain Health St Vincent Regional Hospital, MT $32,300
- Jupiter Medical Center $31,613
- Hospital of Univ of Pennsylvania, PA $29,881
- Mount Sinai Medical Center of Florida, Inc, FL $29,375
- Legacy Good Samaritan Medical Center, OR $27,650
- Broward Health Medical Center, FL $13,841
- Biomedical Research Alliance of New York LLC $5,675
- Tufts Medical Center, MA $5,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.